Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Jun 2023 Results (As of February 1, 2023; n=103) assessing the activity of regorafenib in combination with immune checkpoint inhibitors, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
12 Feb 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Feb 2023.
31 Jan 2023 Primary endpoint ORR replaced with PFS.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com